Please ensure Javascript is enabled for purposes of website accessibility

Merck: Same Plan, With a Twist

By Brian Orelli, PhD - Updated Apr 5, 2017 at 8:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Generic biotech drugs? Really?

Next year may not be Merck's (NYSE:MRK) year, but at least the company has a plan to grow.

It kind of looks like every other pharmaceutical company's plan. But with a twist.

With increasing generic competition and languishing sales of cholesterol-lowering drugs Vytorin and Zetia, which it markets with Schering-Plough (NYSE:SGP), the company is doing its best to replace sales by pushing drugs through its pipeline. It has nine drugs in phase 3 testing and expects to file marketing applications for three drugs next year.

Like GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE), Merck is also planning on moving into emerging markets to make a little extra off of drugs it has already developed. It seems like every pharmaceutical company CEO is touting the emerging markets as the next big thing, but at this point I doubt it'll bring in much more than pocket change for the companies. The emerging markets are a great long-term plan, but until they actually emerge, they're not likely to be a saving grace for the industry.

The big surprise from Tuesday's meeting with analysts is that Merck plans to get into follow-on biologics (biologics are drugs made from cells, rather than chemical processes). The company is behind Teva Pharmaceutical (NASDAQ:TEVA), Novartis (NYSE:NVS), and Dr. Reddy's Laboratories (NYSE:RDY), which already have copycats of biologic drugs on the market in Europe and India, but Merck may have time to catch up. Congress still needs to establish a pathway for approval of follow-on biologics, and then the Food and Drug Administration needs to implement the system. Given the speed at which the government moves, Merck's goal of launching six or more generic biotech products from 2012 through 2017 should be right on target.

I'm having trouble being a Merck bull because I can't see any near-term catalyst to help the company break out of its funk. But long term, investors should remember that this company recovered from losing Vioxx, and it'll likely get back to greatness again -- eventually.

Pfizer and GlaxoSmithKline are Motley Fool Income Investor recommendations. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day trial. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is also an Inside Value selection, and the Fool owns shares of it. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$91.04 (0.50%) $0.45
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.27 (-1.18%) $0.59
Novartis AG Stock Quote
Novartis AG
NVS
$85.22 (-0.70%) $0.60
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$10.01 (-9.25%) $-1.02
GSK Stock Quote
GSK
GSK
$34.70 (-1.59%) $0.56
Dr. Reddy's Laboratories Limited Stock Quote
Dr. Reddy's Laboratories Limited
RDY
$52.19 (-3.14%) $-1.69

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.